#hematological disorder management | Explore Tumblr Posts and Blogs

whattolearntoday · 3 years

Photo

September 8th is...

Ampersand Day - From jotting a shorthand “and” to branding corporate names, this curly, quirky little character is ubiquitously useful.

Iguana Awareness Day - This day is the ideal opportunity to learn about keeping your iguana tame and friendly, how to care for its health and personal grooming, and how to house it comfortably. With the proper care and attention, an iguana can be a wonderful and rewarding pet for many years.

International Literacy Day - The ability to read and write isn’t only important for individuals, but societies as a whole. Some say literacy is a matter of dignity and human rights. Literacy is also an essential foundation of education. The ability to read and write even increases life expectancy.

Pardon Day - Forgiveness, the process by which an offended party chooses to change the way they feel about someone who has committed the offense against them.

Pediatric Hematology/Oncology Nurses Day - Honoring nurses caring for pediatric hematology and oncology patients. These dedicated professionals provide quality nursing care for children, adolescents, and young adults with cancer and blood disorders. Additionally, they provide the highest standard of physical and emotional support to these most precious patients and their families.

Star Trek Day - To today’s audiences, the original Star Trek series can seem hackneyed, corny, and even incredibly racist when viewed through the modern lens. To view it in this way overlooks the incredible strides that were made during it’s production, and how unthinkable some of the elements found within were. Star Trek speaks of a hope-filled future where our nationality no longer matters, and yet each of our personal heritages is still something we can be proud of.

World Physical Therapy Day - When injury or surgery sidetracks a person, they often receive a referral to a physical therapist. Also known as a physiotherapist, this health care professional helps people regain mobility, manage pain, and recover more quickly. Along with helping adults, physical therapists work with children, including babies.

#ampersand #iguana #literacy #pardon #nurses #star trek #physical therapy

16 notes · View notes

vtforpedro · 3 years

Text

health update - long post

hi everyone! I think it's been a month and a half or so since my last update I saw a rheumatologist, had MRIs done, and got my results back from my hematologist SO cancer: still undetectable in my blood, check every 3 months and hope it doesn't show up for a long time lol \o/ I don't think I can say I'm in remission until a certain amount of time has passed but I hope I can say that one day MRIs: actually show some possible improvement with the chiari and spinal fluid flow? and if there IS improvement (like the radiologist who wrote the report had the MRI from a year ago as reference and his findings were all 'normal' compared to april 2020, but it was hard to get an answer out of my neurologist and neurosurgeon if there was solid evidence of physical improvement). but yeah IF there's improvement, that is highly indicative of IIH because my neurosurgeon told me when people with IIH lose weight, the chiari often corrects itself because there's less pressure and more room in the skull for the cerebellar tonsils to be in a normal position. regular chiari that you're born with doesn't do that lol so if there IS improvement with weight loss, then yeah, IIH. even if they don't wanna put in the diagnostic code for it without a lumbar puncture sigh lol I hate typing this because I'm so paranoid it'll all go to shit if I talk about it, but there have been improvements as I've lost weight. I seem to have a couple weeks where my head isn't so severe, mostly manageable with a few awful days. then I'll have a few weeks of it being Really Really bad with a few not-so-awful days. which IIH can do this sort of 'remission' thing but considering it was like 24/7 with no breaks for a year I'd say this is moving in the direction I want it to completely changed my diet a handful of months ago and adjusting it still to be even healthier/more fulfilling. I started using the Noom app (paid sub version) cause it's so focused on psychology instead of 'dieting' and building habits that are sustainable in the long, long-term. I really love it so far. the routine of doing it at the same time every day has already made me feel better mentally about my weight loss journey despite my struggles with losing weight, I am officially down 20lbs \o/ they say for improving/curing IIH, you need to lose 10-20% of your body weight. well, 10% down! time to lose another 20, but I don't find it intimidating and I'm not dreading it. it's hard to have hope, especially on really bad weeks, but I'm taking it one day at a time. definitely not cured but I'm aiming for 40lbs more (so 60 altogether) and by then, maybe, just maybe.... rheumatologist/autoimmune disorder results: so I went to a rheum cause I got that positive autoimmune disorder blood test with the possibility of lupus or scleroderma. she said that she gets so many hematology patients because leukemia and lymphoma have blood antibodies, so it will almost always show up as positive on this antibody test and most people actually won't have an additional autoimmune disorder. I don't have a lot of symptoms of lupus or scleroderma according to her, so she told me don't worry about autoimmune disorders for three months. don't think about them. we'll repeat labs then and see what they say. so that's good news so far and I hope it remains that way 15%+ of the population will test positive on the same test without having any health issues, which I found interesting. and I asked since I already have an autoimmune disorder, tho it's endocrine versus rheumatic, if that would also trigger a positive result and she said yes it would! so yeah... I hope by late July I can still say I don't have an additional autoimmune disorder I see a gastroenterologist tomorrow for the bloating/abdominal pain and other stuff I've been having. I have a feeling I'll be given some antacids (or w/e they're called when it's prescription strength) and that will improve. but jfc I'm up to eight specialists now lol NINE doctors are following my health god it's such a shitty feeling especially when I can barely trust any of them. at

least they all believe me now, but it cost me my quality of life and mental health to even get to this point so I'm still feeling pretty fucking bitter and angry about it all you know what's really hard about completely changing my diet + starting new medications/supplements? for some reason at the beginning of all of this when I was experiencing repeated trauma at the ER, my brain developed a phobia of allergic reactions, despite the fact that I've never had one for food/medicine (I'm talking anaphylactic reactions). so now every single new thing I eat, every new med or supplement, I go through panic attacks for days on end thinking I'm going to die before it starts easing. also, anxiety makes your throat feel like it's closing up and that it's harder to breathe already so lmao fun times. I literally never thought about this in all my life and I never even experienced an allergic reaction to develop this intense fear, so you know. fuck doctors for putting me through this when it was all so unnecessary sigh anyway. still can't watch videos, tv, movies, read, bend over, walk for longer than 5 minutes, and can't talk for long either because it'll trigger a head episode. I'm terrified I won't be able to do these things ever again, but I'm still aiming for my goal weight no matter what and I know I can get there bouncing between misery and hopelessness, and slightly less misery and some hope right now, but I guess that's better than it's been for a year, right? sorry for rambling. I feel like a lot has gone on but I've also had the biggest gaps between doc appts in a while which is a relief just because I can't stand being in medical buildings or around doctors anymore completely vaccinated too, so that's another relief, but I'm wearing masks until americans get their heads out of their asses and we start seeing little to no community spread cause I am still immunocompromised. wouldn't it be nice if people like, idk, cared about each other ok sorry! I hope you're all well and healthy and safe. I love you very much and I'm grateful for your support, forever and always! <3

#medical #personal #long post #i'm so fucking tired guys #just absolutely exhausted 24/7 #i desperately need therapy because my mental health is HOO not good not good at all #whenever i can finally talk long enough to have therapy I'm gonna ask them to send the bill to all of the doctors that ruined me lmao

30 notes · View notes

techsciresearch · 3 years

Text

Equipment & Consumables Product Segment to Dominate the United States Biobanks Market | TechSci Research

Rise in demand for affordable drugs and ongoing research and development activities is expected to drive the demand for United States biobanks market for the forecast period.

According to TechSci Research report, “United States Biobanks Market By Type (Population Based Biobanks v/s Disease Oriented Biobanks) By Ownership (National/regional agency, Non-profit Organization, Universities, and Private Organization) By Product (Equipment & Consumables, Media, Software & Services) By Specimen Type (Blood Products, Solid Tissue, Cell Lines, Nucleic Acid, Others) By Application (Therapeutic v/s Research) By End User (Academic Institutes, and Pharma & Biotech Companies, Others), By Region, Company Forecast & Opportunities, 2026”, the United States biobanks market is expected to witness significant growth for the next five years. Biobanking is a procedure that is used to collect and preserve biological specimens which are used for diagnosis, research activities, and biodiversity studies. The presence of different types of biobanks such as disease-oriented biobanks, tissue banks, blood banks, among others are encouraging consumers to preserve their samples in biobanks which are bolstering the market growth.

The rise in genomic research activities coupled with the expansion of application areas for bio-banked samples is driving the market growth for the forecast period. An increase in the incidence of auto immune diseases such as cancer and blood disorders in addition to the surge in the population suffering from chronic diseases is contributing to boost the market growth. The surge in popularity for personalized medicine and genetic testing is considered the key driver responsible for the market growth. An increase in the number of established stem cell biobanks along with the growing application of stem cells in cell therapy, toxicology, drug development, developmental biology is leading to the rapid rise in the number of stem cell banks, thereby creating lucrative opportunities for the biobank market growth.

The occurrence of COVID-19 outbreak across the world which has been declared as a pandemic by the World Health Organization has affected several countries adversely. Leading authorities in the United States imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. Coronavirus-affected patients started suffering from shortness of breath along with coughing and sneezing along with the other symptoms.

United States authorities increased the capacity of hospitals as a greater number of patients were getting affected daily and getting admitted into the hospital facilities. To contain the spread of novel coronavirus, high-quality COVID-19 specimens are required for diagnostic and research purposes which can be stored and preserved in biobanks. Biobanks are supporting the drug discovery process to ensure effective treatment along with providing quality samples for the clinical research process which in turn is fueling the growth of the market in this period.

However, the high cost involved in automation may create a hindrance in the growth of the biobanks market.

Browse XX Figures spread through XX Pages and an in-depth TOC on "United States Biobanks Market”.

https://www.techsciresearch.com/report/united-states-biobanks-market/7701.html

United States biobanks market is segmented into type, ownership, product, specimen type, application, end user, regional distribution, and company. Based on specimen type, the market can be divided into blood products, solid tissue, cell lines, nucleic acid, and others. The blood products specimen type segment is expected to account for major market share in the next years as it is the most collected specimen used for diagnostic purposes. The surge in the prevalence of hematological diseases and other blood disorders is leading to accelerating the market demand.

Also, these are the source for DNA and RNA which can provide insight into the lineage and history of the person. Based on application, the market can be bifurcated into therapeutic and research. The therapeutic segment is expected to hold a significant share in the biobanks market in the forecast period. Regenerative medicines are in high demand owing to fueling demand for high-quality biosamples and growing research in regenerative medicine is fostering the market growth.

Thermo Fisher Scientific Inc., Hamilton Company, Brooks Automation, Inc., VWR Corporation, LLC, Promega Corporation, Becton, Dickinson, and Company, RUCDR Infinite Biologics, LabVantage Solutions Inc., US Biolab Corporation, Inc., ProteoGenex, Inc., Cureline, Inc., Bay Biosciences LLC, Geneticist Inc, BioLifeSolutions Inc. are the leading players operating in United States biobanks market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several biobanks service providers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7701

Customers can also request for 10% free customization on this report.

“High-end investments by the major players to upgrade the existing infrastructure to advance the platform and tools used in genetic studies are significant factors contributing to the market growth. Technological advancements such as the use of 3-D printing for tissue samples and mini-organ creation are also contributing to propel market growth. Adoption of virtualization, digitalization, and precision medicine to provide effective treatment coupled with the launch of novel products by the major players is boosting the growth of the market in the forecast period till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United States Biobanks Market By Type (Population Based Biobanks v/s Disease Oriented Biobanks) By Ownership (National/regional agency, Non-profit Organization, Universities, and Private Organization) By Product (Equipment & Consumables, Media, Software & Services) By Specimen Type (Blood Products, Solid Tissue, Cell Lines, Nucleic Acid, Others) By Application (Therapeutic v/s Research) By End User (Academic Institutes, and Pharma & Biotech Companies, Others), By Region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of United States biobanks market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of United States biobanks market.

Browse Related Reports:

Global Bio Preservation Market By Product (Media, Equipment, Accessories, Alarms & Monitoring System, Incubators, Centrifuges, Other), By Biospecimen (Human Tissue Samples, Stem Cells, Organs, Others), By Cell Providers (CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells), By Application (Therapeutic, Research, Clinical Trials, Others), By End User (Biobanks, Gene Banks, Hospitals, Others), By Region, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/bio-preservation-market/4711.html

United States Biomedical Refrigerators & Freezers Market By Product (Pass-Through, Explosion Safe, Flammable Storage, Combo/Dual Temperature, Ultra Low Freezers, Plasma Freezers, Others), By Storage (Blood, Vaccines, Plasma, DNA, Flammable Chemicals, Others), By Temperature (RNA & DNA {-70C to -80C}, Vaccines {-30C to -40C} & Others), By Capacity (138L, 169L, 221L, 230L, 426L, 690L, Others), By End-User (Hospitals, Pharmacies, Diagnostic Centers, Research Laboratories, Blood Banks), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/united-states-biomedical-refrigerators-and-freezers-market/7502.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #United States Biobanks Market #Healthcare #Biobanks Market #US Biobanks Market Size #US Biobanks Market Forecast #Consumer Healthcare

2 notes · View notes

irispublisherscancerresearch · 3 years

Text

Eosinophilia and Neutrophilia Associated with Anti- PD-1 use in Metastatic Non-Small Cell Lung Cancer – A Case Report-Iris Publishers

Authored by Yasir Khan*

Abstract

The use of immunotherapy has dramatically changed the way many cancers are treated with several studies having looked at the relationship between eosinophils and immunotherapy. This case study reports nivolumab induced eosinophilia and neutrophilia with no other systemic adverse effects in a patient with metastatic non-small cell lung cancer. A 61-year-old woman with Eastern Cooperative Oncology Group performance status 1 was diagnosed with metastatic non-small cell lung cancer without any driver mutations and was commenced on nivolumab after progressing on platinum doublet therapy. She had mild eosinophilia and neutrophilia at baseline in the context of a lower respiratory tract infection which became more pronounced with the introduction of nivolumab. Nivolumab was ceased at week-26 due to significant eosinophilia and reached peak levels at week-35. She developed postural hypotension during the course of her disease and prednisolone was commenced to treat possible adrenal insufficiency from metastasis. The introduction of steroids led to the improvement in eosinophilia and neutrophilia. She had stable disease for 8 months after commencement of immunotherapy before progression of disease leading to clinical deterioration and death. Asymptomatic eosinophilia and neutrophilia is an extremely rare toxicity of immune checkpoint inhibitors. Its significance as prognostic and predictive marker needs to be researched further.

Keywords: Immunotherapy induced eosinophilia; Neutrophilia; Nivolumab.

Introduction

Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1 and CTLA-4 are routinely used in clinical practice in multiple tumour types. These drugs are very effective especially for solid organ malignancies with high mutational load but carry a wide spectrum of toxicities driven by over stimulation of immune system. Immunerelated adverse events (irAEs) range from low grade toxicities to severe toxicities which can potentially be life threatening in some cases. Among some of the uncommon side effects, immunotherapy induced eosinophilia is a rare toxicity with only a few documented cases and mostly associated with eosinophilia related systemic manifestations or with additional toxicities. There are well established guidelines for treating common irAEs but little is known about the optimal management of rarer toxicities like asymptomatic eosinophilia. This case study reports nivolumab induced eosinophilia and neutrophilia with no other systemic adverse events in a patient with metastatic non-small cell lung cancer.

Case Report

A 61-year-old woman was admitted with the diagnosis of lower respiratory tract infection with investigations leading to a diagnosis of stage IV adenocarcinoma of the lung without targetable mutations. She had a left lung mass, hilar nodes enlargement, malignant ipsilateral pleural effusion and liver metastases. PDL1 status was not obtained as there were no standard treatments based on PD-L1 levels at that time. She was a smoker and had Eastern Cooperative Oncology Group (ECOG) performance status 1.

Due to prescribing restrictions applicable at that time, she was initially commenced on carboplatin and gemcitabine chemotherapy before progression of disease. Second line pemetrexed was given but it failed to provide any clinical benefit. She was then commenced on nivolumab monotherapy. Initial interval scan suggested worsening of disease, however given there was no clinical deterioration, she was given the benefit of doubt and nivolumab was continued on the assumption of pseudo progression. Her baseline neutrophils and eosinophils count were mildly elevated (Table 1). Of note this was in the setting of lower respiratory tract infection. The elevated eosinophil counts were persistent but still mild at the commencement of nivolumab. Both neutrophilia and eosinophilia were more pronounced at 14 weeks post-nivolumab and reached peak levels at 35 weeks (Figure 1) (Table 1).

Table 1:Serial full blood counts (FBC).

Nivolumab was stopped after 13 cycles due to worsening of eosinophilia and neutrophilia in the context of stable disease on imaging. Patient did not have any other systemic features at the time when nivolumab was stopped. Possible differential diagnosis at that stage included paraneoplastic phenomenon, immune mediated toxicity, and myeloproliferative disorder. She started to deteriorate clinically with recurrent falls. Adrenal insufficiency was considered to be the most likely diagnosis based on the clinical features of postural hypotension, hyponatremia, hyperkalemia and finding of left adrenal metastasis on repeat imaging. This diagnosis was further confirmed by inadequate response of adrenal glands to short synacthen test. She was commenced on prednisolone to correct adrenal insufficiency which also led to the improvement in neutrophilia and eosinophilia. Eventually disease progression was recorded soon afterwards along with clinical deterioration predominantly from progression in the lungs causing respiratory failure and death. She had 14 months of survival since diagnosis of the cancer. Progression free survival on immunotherapy was 8 months with stable disease being the best response.

Discussion

A well-known cause of hyper eosinophilia is the DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome. Common features of DRESS include blood eosinophilia, fever, skin changes, facial oedema, visceral involvement, and atypical lymphocytes [1]. DRESS has been reported to be associated with immunotherapy. Mirza et al presented a case of patient who developed DRESS after combination ipilimumab and nivolumab for melanoma and successfully treated with steroids [2]. Voskens et al also presented a case of DRESS syndrome following ipilimumab for melanoma which responded to steroids [3]. Furthermore, there have been other case reports documenting relationship between immunotherapy and eosinophilia with uncommon systemic manifestations. Khoja et al. presented a case of a patient who developed eosinophilic fasciitis and cerebral vasculitis one month after completing an 18-month course of pembrolizumab for metastatic melanoma [4]. Okano et al presented a case of a patient with hypophysitis with associated eosinophilia following nivolumab for metastatic lung cancer [5]. To our knowledge, there are only two case series published in literature in regard to nivolumab induced eosinophilia, however a majority of those patients also experienced other irAEs of various grades [6,7]. In addition to this, there have been five published case reports of nivolumab induced eosinophilia to date [2,8-11]. Our report documents a case with isolated hematological abnormalities including eosinophilia and neutrophilia without systemic features in a patient treated with nivolumab for metastatic non-small cell lung cancer (NSCLC) which is a rare toxicity of anti-PD-1 antibodies.

The role of eosinophils in tissue homeostasis is not fully understood. Nevertheless, certain conditions have a well-known association with eosinophilia such as allergic diseases, infectious diseases (especially parasitic infections), autoimmune diseases (especially adrenal insufficiency) and haematological disorders. Eosinophilia has also been described as a paraneoplastic phenomenon of many solid organ malignancies and is most associated with an advanced stage and poor prognosis [12]. Eosinophils can also play a role in pathogenesis through depositing granules which can have both direct toxic effects and recruit as well as activate other inflammatory cells [13]. A hypereosinophilic syndrome (HES) in which there are symptoms from a high eosinophil count in blood or tissue has been described with the underlying cause often never found despite extensive investigation [12,13]. There are various mechanisms reported in the literature to explain pathophysiology of eosinophilia. Immune proteins and cytokines like interleukin-3 (IL-3) and interleukin-5 (IL-5) have been associated to play a role in elevated eosinophil counts [14,15]. Our patient also had neutrophilia in addition to eosinophilia. Neutrophilia is induced by granulocyte macrophage colony stimulating factor (GM-CSF). Interaction and interplay of immune proteins like GM-CSF, IL-3 and IL-5 leads to activation of multiple cell lines. The role of eosinophils in tumour microenvironment is not well known and may possess anti-tumour effects in some cases while promoting tumorigenesis in others [16]. Its value as prognostic and predictor factor is also unclear. Eosinophilia at diagnosis of the cancer has been linked with poor prognosis in some advanced malignancies [17,18]. On the other hand, some pre-clinical studies indicate immunotherapy induced eosinophilia may be a predictor of response to treatment. In our case, when immunotherapy was stopped after 13 cycles the best response achieved with immunotherapy was stable disease only. As eosinophilia pre-dated the start of immunotherapy, at least in our case, it does not seem to be associated with treatment response or effectiveness.

Conclusion

Asymptomatic eosinophilia and neutrophilia is an extremely rare toxicity of ICI. Development of eosinophilia in the setting of immunotherapy use needs to be studied further to delineate its role as both prognostic and predictive marker.

Read More....FullText

For More Articles in Advances in Cancer Research & Clinical Imaging please click on https://www.irispublishers.com/acrci/

Indexing List of Iris Publishers: https://medium.com/@irispublishers/what-is-the-indexing-list-of-iris-publishers-4ace353e4eee

Iris publishers google scholar citation articles: https://scholar.google.co.in/scholar?hl=en&as_sdt=0%2C5&q=irispublishers&btnG=

#IrisPublishers #IrisPublishersllc #Cancer #imaging #immunotherapy

2 notes · View notes

fanfansfury · 3 years

Text

How it started...

My story can be considered a complex one starting from my childhood. For as long as I can remember, I have medical issues that I haven’t ever gotten a real answer for.

As a child in elementary school, I remember being sick way more often than my peers. Stomach bugs, infections, you name it. It felt constant. I also had an amazing ability to pass out unannounced or with very little warning. I’ve always loved being active in sports and working out, but as I have gotten older, I have seemed to build an intolerance to exercise.

My medical history is significant for chronic anemia, low blood pressure, B12 deficiency, anxiety and depression, and a bladder disease named Interstitial Cystitis. My anxiety increased as I understood more that I didn’t’ have control on whether I would pass out unexpectedly or not.

As years went on, I was able to recognize the signs of low blood pressure and could sometimes avoid passing out if I caught it in time. I lived a mostly normal young adulthood full of college and grad school experiences typical of most people my age. I got married to a wonderful man, Sam FanFan, in 2011 and soon had our first daughter, Kyla Maresa, inElla will decrease her sound substitutions in connected speech, with 1-3 prompts or cues from an adult, in 4 out of 5 recorded opportunities. 2012. Kyla was also no stranger to medical issues as a baby, as she gave us a few heart attacks and hospitalizations. Now, as an active 8 year old, she is an accomplished dancer and student, who has seemed to grow out of a lot of issues we used to see with her frequent infections and weak respiratory system. (YAY!)

Fast forward to our second daughter, Kaelani Burke, who was born in 2017. Her birth itself was uneventful. Three hours after she was born, I began hemorrhaging. It was traumatic to say the least, for both me and Sam. To this very day, I am beyond thankful for my labor and delivery nurses who caught the hemorrhaging in time to save my life.

Kaelani has been through the wringer in her short 4 years of life. She managed to be diagnosed with 12 ear infections by the time she was 20 months old. Oral antibiotics didn’t seem to touch them and we needed to resort to injections almost every time. At 21 months, we knew surgery couldn’t be avoided anymore and she had her adenoids removed and tubes placed in her ears. Neither of which seemed to help avoid recurrent ear infections anyway.

In late 2019/early 2020, Kaelani began having severe nosebleeds. At first, Sam and I chalked it up to dry air and got humidifiers for almost every room in the house. The remedying we tried did not help slow the bleeds down and they were happening multiple times a day, both at home and daycare. By the end of January 2020, Kaelani began to fall asleep after the bleeds. I immediately took her back to her ENT. After about 4 very frustrating appointments and conscious cauterizations, they drew her blood. We were immediately told hemotology/oncolocy was waiting for us upstairs. Though they couldn’t pinpoint the exact disease at that point in time, it was clear to the team Kaelani was suffering from a rare vascular disease and it warranted further investigating.

The next day, Kaelani was brought in for surgery to cauterize the blood vessels that seemed to be causing the problem. This procedure was supposed to be in-and-out to merely stop the bleeding. When Kaelani was in recovery, her surgeon came to talk to Sam and I to report that while she was cauterizing, she saw many telangiectasias (abnormal blood vessels normally found in older adults) in her nasal lining that were quite concerning to her. We were then admitted and by the end of the night, had seen hematology, ENT, and genetics. She was brought in for an ultrasound of her major organs to make sure there wasn’t active bleeding. We were discharged with what seemed like a million appointments ahead of us. Genetics and Hematology are confident she has a very rare blood disorder called HHT (Hereditary Hemorrhagic Telangiectasia), but in order for this diagnosis to be officially on her medical record, a parent needs to be diagnosed. On her medical record now, it states (suspicion of HHT), which may not always get her the help she needs say she were to have a seizure or brain bleed. Now, let’s cue the blood issues I have had my entire life and assume the connection here. However, since I am currently asymptomatic, this will be no easy feat. Especially since one month after this ordeal, COVID-19 hits and elective appointments are not at the top of anyone’s list.

Since last March, I have seen cardiology, urology, pulmonology, and hematology. As suspected, because I am asymptomatic at this point in my life, not much is being found to help Kaelani’s case.

However, during the pursuit of Kaelani’s diagnosis, my chronic anemia is going strong, so my hematologist decided it was time to do further digging. My anemia is NOT iron related. I am not iron deficient. So, we assumed it was nutritional. I spent a few months on vitamins that should have improved my anemia, even just a little bit. It got worse.

That brings me to this past week. After months of trying to figure out why my anemia continues to get worse, my hematologist decided it was time to do a bone marrow biopsy. In case you were wondering, the biopsy is quite painful.

Now... we wait. Results are expected by March 4...

Stay tuned.

1 note · View note

eyeredtranscriptionservices · 4 years

Text

Why Is Everyone Talking About Hematology Transcription?

The field of hematology is experiencing exemplary medical breakthroughs. Are you looking forward to hiring the most affordable, prompt, reliable, accurate, and meticulous hematology transcription solutions? If yes, then you need to find out more reasons as to why the medical industry is highly relying on the hematology transcription services.

Meaning of Hematology

The medical specialty comprising of the science of blood, blood-producing organs, a blood disorder, Hematology emphasizes special diagnosis, treatment, and prevention of diseases associated with blood and blood-related disorders. This specialty deals with many disorders related to blood cells, platelets, as well as, coagulation system.

Hematology, the special medical branch that aims to study the diagnosis, problems, functioning, and treatment of elements of human blood, is extremely essential in analyzing etiology. The branch deals with finding out a source of any blood-related disease.

It involves preventing and treating the diseases that affect the production of blood and its components, such as, platelets, bone marrow, blood vessels, coagulation mechanism, spleen, blood proteins, and hemoglobin. Examples of diseases related to this are blood clots, hemophilia, other bleeding disorders, as well as, blood cancers such as lymphoma, multiple myeloma, and leukemia. The major laboratory work that studies the blood is frequently performed by a well-trained medical laboratory scientist or a medical technologist.

Significance of Hematology Transcription Service

The work of a hematologist involves the generation of voluminous notes along with lab reports to arrive at the most perfect diagnosis. The aim of hematologist is also to deliver the best possible results and care to the affected patients. Hematologists may specialize in the following areas of special interest-

Treating major bleeding disorders such as idiopathic thrombocytopenic purpura and hemophilia

Treating malignancies related to hematology such as leukemia and lymphoma (cancers)

The work associated with blood bank and the science of blood transfusion

Treating hemoglobinopathies

Stem cell and bone marrow transplantation

In addition to this, their duty involves positive interaction with highly-qualified medical professionals such as oncologists, lab technicians, and other medical technologists, so that they are in a position to understand the underlying causes and effects of various blood and blood-related diseases. These are the reasons why Hematologists look forward to partner with the most reliable hematology transcription service providers. These transcription service providers are not only well-versed with the most relevant medical terms but they are also capable of coming up with the most reliable, accurate, and efficient transcripts that ensure quality care and safety of the patient.

Hematology-oncology transcription services are offered in the following areas:

Cancer treatment

chemotherapy

experimental treatments

Biological therapy

ablation therapy

blood transfusions

transplants

blood and bone marrow donations

And more

Hematology transcription process:

The medical client will upload the dictation for the transcription manager

The voice files will be run through an internally developed voice recognition system or engine

A medical hematology transcriptionist will prove the report with voice file word by word

Then the report will be read by a transcriptionist without the assistance of voice file and he/she will re-listen without any doubtful areas if any

A transcriptionist editor will proof-read the report with voice file word by word

The transcriptionist editor will read this report without voice file and re-listen to it without any doubtful areas if any

The final report is then uploaded to the hematology transcription manager or directly to the client’s platform

Feedback from the client is taken for any improvement

What is the specialty of hematology transcription services?

Most of the medical providers look forward to hiring the transcription services of a team full of expert professionals who are having hands-on experience in serving the diverse range of clients in the field of hematology. The highest possible quality services, accuracy, and reliability of the transcriptionists allure the medical providers to try the third-party hematology transcription services.

The best part about hiring a professional hematology transcriptionist for your hospital or clinic is that you will receive assured technological relevance. At the same time, your medical integrity will be maintained. The hematology transcriptionists adopt the most modern tools, methods, and technologies for efficiently and effectively documenting your critical hematology reports. Further, dictation modes are offered very easily according to the choice and preference of the clients.

Hematology transcription services should not only be accurate and dependable but also HIPAA compliant. Further, let us discuss the other benefits of partnering with a well-qualified and experienced Hematology transcription service provider-

Cutting-edge tools, methods, and technologies that assure speed and precision in the work

Accessibility of comprehensive and affordable packages fulfilling the diverse needs of the clients of the medical industry

Full compliance with the rules, guidelines, and regulations of HIPAA and its processes

Medical professionals having hands-on experience for ensuring relevance, accuracy, and speed

Fully furnished files presented in the form of clients’ choice

#hematology transcription #medical transcription #transcription services #transcription company #Healthcare #medical

1 note · View note

blackkudos · 6 years

Text

James Edward Bowman

James Edward Bowman, MD, FASCP, FCAP (February 5, 1923 – September 28, 2011) was an American physician and specialist in pathology, hematology, and genetics. He was a professor of pathology and genetics at the Pritzker School of Medicine at the University of Chicago.

Life and career

James Edward Bowman was born on February 5, 1923, in Washington, D.C., the son of Dorothy (Peterson), a homemaker, and James Edward Bowman, Sr., a dentist. He attended Dunbar High School. He earned his undergraduate and medical degrees from Howard University in 1943 and 1946. He did medical internships at Freedmen's Hospital in Washington D.C. and at Provident Hospital in Chicago, Illinois. His residency in pathology was at St. Luke's Hospital in Chicago where he was the first African American resident.

Following residency, Bowman served as chair of pathology at Provident Hospital. He was drafted again and spent 1953 to 1955 as chief of pathology for the Medical Nutrition Laboratory at Fitzsimons Army Hospital in Aurora, Colorado. After leaving the military Bowman decided to move overseas. “My wife and I decided that we were not going to go back to anything that smacked of segregation,” he recalled. He became chair of pathology at Nemazee Hospital in Shiraz, Iran. “We were recently married, so we took a chance,” he said. “It changed our lives completely.” Their daughter, Valerie, was born in Iran.

In Iran Bowman saw many diseases for the first time. “I saw smallpox, brucellosis, rabies, all sorts of things,” he said. One of the most common diseases among certain ethnic groups in Iran was favism, a metabolic disease caused by an enzyme deficiency in red blood cells. The mutation, which is the most common human enzyme defect, renders those who have it unable to break down a toxin found in fava beans. Favism fit with Bowman’s lifelong focus on inherited blood diseases and led to a series of important discoveries about the genetics of these diseases and the populations they affect, especially in the Middle East, Africa and America. It enabled him to travel all over the world collecting blood samples for DNA testing. It also led to frequent contacts and collaborations with University of Chicago researchers, who had first described the enzyme deficiency (glucose-6-phosphate dehydrogenase deficiency, or G6PD) and its connection with antimalarial medications.

Bowman joined the faculty of the University of Chicago in 1962 as an assistant professor of medicine and pathology and director of the hospital’s blood bank. He was promoted to full professor and director of laboratories in 1971. From 1973 to 1984, he directed the Comprehensive Sickle Cell Center of the University of Chicago, funded by the National Institutes of Health. He was a member of the national advisory group that urged the Nixon administration to initiate the inception of the Comprehensive Sickle Cell Center, which served as a model of patient-centered disease management and research. He also served as assistant dean of students for minority affairs for the Pritzker School of Medicine from 1986 to 1990.

In 1972 Bowman declared that mandatory sickle cell screening laws were “more harmful than beneficial.” These laws could “revive many of the past misadventures and racism of eugenics movements,” he argued at the time, adding that adult screening programs create “inaccurate, misleading, politically motivated propaganda which has left mothers frantic.” In 1973, he was named to two federal review committees designed to oversee sickle cell screening and education and to evaluate laboratory diagnostic techniques.

Bowman was certified by the American Board of Pathology in pathologic anatomy (1951) and clinical pathology (1952).

He was the first tenured African-American professor in the University of Chicago's Biological Sciences Division. He served as the medical school's Assistant Dean of Students for Minority Affairs from 1986 to 1990. He was a fellow of the Hastings Center, a bioethics research institution.

He was married to educator Barbara Bowman and they had one daughter, Valerie Bowman Jarrett, who is a Senior Advisor to President Barack Obama.

Dr. Bowman died of cancer on September 28, 2011, at the University of Chicago Medical Center, at the age of 88.

Selected publications

Bowman published numerous articles and books, including:

Books

Bowman, James E.; Robert F. Murray (1998). Genetic Variation and Disorders in Peoples of African Origin. Hopkins. ISBN 978-0-8018-5884-0.

Bowman, James E. (1983). Distribution and Evolution of Hemoglobin and Globin Loci. Proceedings of the Fourth Annual Comprehensive Sickle Cell Center Symposium on the Distribution and Evolution of Hemoglobin and Globin Loci at the University of Chicago, Chicago, Illinois, U.S.A., October 10–12, 1982. Elsevier. ISBN 978-0-444-00793-3.

Journal articles

Bowman, James E.; Robert R. Brubaker; Henri Frischer; Paul E. Carson (September 1967). "Characterization of Enterobacteria by Starch-Gel Electrophoresis of Glucose-6-Phosphate Dehydrogenase and Phosphogluconate Dehydrogenase". Journal of Bacteriology. American Society for Microbiology. 94 (3): 544–551. PMC 251920. PMID 5340676.

Shaw, Richard F.; Ruth Winter Bloom; James E. Bowman (September 1977). "Hemoglobin and the genetic code: Evolution of Protection against Somatic Mutation". Journal of Molecular Evolution. Springer New York. 9 (3): 225–230. doi:10.1007/BF01796111. PMID 864725.

Bowman, James E. (May 1989). "Legal and Ethical Issues in Newborn Screening". Pediatrics. 83 (5): 894–896.

Bowman, James E. (March 1991). "Prenatal screening for hemoglobinopathies". American Journal of Human Genetics. 48 (3): 433–438. PMC 1682982. PMID 1998329.

Bowman, James E. (1998). "Minority Health Issues and Genetics" (Proceedings of The National Dialogue on Genetics, College Park, Maryland, March 21–22, 1998). Community Genetics — Public Health Genomics. 1 (3): 142–144. doi:10.1159/000016152. PMID 11657303.

Bowman, James E.; Giselle Corbie-Smith; Peter Lurie; Sidney M. Wolfe; Arthur L. Caplan; George J. Annas; Amy L. Fairchild; Ronald Bayer (2 July 1999). "Tuskegee as a Metaphor". Science. 285 (5424): 47–8; author reply 49–50. doi:10.1126/science.285.5424.47b. PMID 10428701.

Bowman, James E. (June 2000). "Technical, Genetic, and Ethical Issues in Screening and Testing of African-Americans for Hemochromatosis". Genetic Testing. 4 (2): 207–212. doi:10.1089/10906570050114920. PMID 10953961.

Bowman, James E. (Autumn 2001). "Genetic Medicine: A Logic of Disease (review)". Perspectives in Biology and Medicine. The Johns Hopkins University Press. 44 (4): 617–618. doi:10.1353/pbm.2001.0061.

Wikipedia

#James Edward Bowman

10 notes · View notes

karmalkar911 · 2 years

Text

Dr. Abhishek Karmalkar - General Physician Doctors in Pimpri Chinchwad

General Physician (MD - General Medicine, MBBS)

Dr. Abhishek Karmalkar’s main objective is to serve INDIA through medicine by making people healthy and excel in profession and serve towards humanity.

Dr. Abhishek Karmalkar is an expert in handling the deadly corona virus, has taken in-charge as chief intensivist and successfully treated more than 2000 critical corona patients and innumerable ward cases.

He is excelled in early recognition and management of diabetes. His speciality includes managing all complication of diabetes including diabetic foot, neuropathy, end organ damage like nephropathy. He has also expertise in management of various infectious diseases and Cardiology, Hepatology, Hematology, Nephrology and Neurology diseases.

Education Details

Dr. Abhishek Karmalkar completed his MD (Medicine) from Grant Government Medical College, Mumbai in 2010 and MBBS from B. J. Medical College, Pune in 2005. Also, he has done Diploma in Critical Care Medicine from ISCCM in 2012.

Dr. Abhishek Karmalkar is a well-known doctor specialising in General Physician in Pimpri Chinchwad. He has over 9 years of experience practising medicine in various hospitals and clinics. Dr. Abhishek Karmalkar is now working with Sterling Multispeciality Hospital. Dr. Abhishek Karmalkar has previously been associated with B. J. Medical College, Pune, Health Box Polyclinic (Self owned). Dr. Abhishek Karmalkar specialises in Diabetes Management, Thyroid Disorder Treatment, Critical Care Medicine, Hypertension Treatment, Cardiac Care, Dengue Fever Treatment. Apart from hospital affiliations, He has been working actively in various fields. Dr. Abhishek Karmalkar is an alum of Grant Medical College and Sir JJ Hospital, Mumbai where He earned a MD – Medicine. Thereafter, Dr. Abhishek Karmalkar earned Advanced Certificate Course In Diabetes from American Diabetes Association.

What does a general physician do?

A general physician has an extended list of duties due to the fact he/she is the first point of contact for maximum patients. As such, these are some things that physicians do:

Diagnose conditions and injuries

Conduct routine check-ups

Recommend clinical tests for further diagnosis

Assess a affected person`s condition and evaluate clinical history

Prescribe medicine and treatment

Assist in routine surgical operation

Counsel patients on well-being and right self-care

Maintain patient records for ideal preventive care

At Health Box Polyclinic we have we have most of the best general physician in pimpri chinchwad who’re notably professional and expert in diagnosing a host of various clinical conditions. Our state of the art technology and equipment permits for the early detection of diseases, and we’ve a extensive kind of specialists who can take up the case post diagnosis.

Why you choose Dr. Abhishek Karmalkar?

Health Box Polyclinic Clinic is committed to providing the best medical treatment and diagnosis facilities. Physician consultation Including ECG Test, Sugar Check-Up, Full body check-up facility is available in the same clinical premises by expert general physician doctor in pimpri chinchwad. Furthermore, it has a well-facilitated diagnostic centre to provide medical treatment along with the diagnosis facility to the patients. Certainly, Dr. Abhishek Karmalkar is the man behind the establishment of this medical facility center. Most noteworthy this is his effort to provide the best medical facilities including diagnosis facility at the same place, as a result to the residents of the pune.

#General Physician Doctors in Pimpri Chinchwad

0 notes

sunriselifecare · 2 years

Text